The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study

Trazpiroben is a dopamine D(2)/D(3) receptor antagonist under development for the treatment of gastroparesis. This phase I, open‐label, randomized, two‐way crossover study (NCT04121078) evaluated the effect of single‐dose intravenous rifampin, a potent inhibitor of the organic anion transporting pol...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukker, Jatinder K., Dukes, George, Tolkoff, Max, Wang, Lisi, Almansa, Cristina, Huh, Susanna Y., Nishihara, Mitsuhiro, Ramsden, Diane, Chen, Chunlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199876/
https://www.ncbi.nlm.nih.gov/pubmed/35460165
http://dx.doi.org/10.1111/cts.13274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199876/
https://www.ncbi.nlm.nih.gov/pubmed/35460165
http://dx.doi.org/10.1111/cts.13274

Ejemplares similares